Activating HER2 mutations in HER2 gene amplification negative breast cancer

類似資料

• HER2 mutated breast cancer responds to treatment with single agent neratinib, a second generation HER2/EGFR tyrosine kinase inhibitor
  著者:: Ben–Baruch, Noa Efrat, 等
  出版事項: (2015)
• HER2 activating mutations are targets for colorectal cancer treatment
  著者:: Kavuri, Shyam M., 等
  出版事項: (2015)
• Her4 and Her2/neu Tyrosine Kinase Domains Dimerize and Activate in a Reconstituted in Vitro System
  著者:: Monsey, John, 等
  出版事項: (2010)
• Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
  著者:: Punturi, Nindo B., 等
  出版事項: (2021)
• Carboxyl Group Footprinting Mass Spectrometry and Molecular Dynamics Identify Key Interactions in the HER2-HER3 Receptor Tyrosine Kinase Interface
  著者:: Collier, Timothy S., 等
  出版事項: (2013)